Avidity Nanomedicines
425 employees on LinkedIn · 5 known investors
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
Investors · 5
Competitors · 2
by search overlap
IQVIA43 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Bioworld43 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Avidity Nanomedicines for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Avidity Nanomedicines do?
- Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
- Who are Avidity Nanomedicines's investors?
- Avidity Nanomedicines's investors include Avoro Capital Advisors, Brace Pharma, F-Prime Capital, Frazier Life Sciences, Moore Venture Partners.